Drugs / RLY-5836
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05759949 | Mar 2023 → Mar 2025 | PIK3CA-related overgrowth spectrum, hormone receptor-positive breast cancer | Relay Therapeutics, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RLY-5836 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05759949 ↗ |
| Action | Inhibit | “RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.” NCT05759949 ↗ |
| Route | Oral | “RLY-5836 is a mutant-selective, oral PI3Kα inhibitor.” NCT05759949 ↗ |